Rivista di Psichiatria, published by PENSIERO SCIENTIFICO EDITORE, stands as a significant contributor to the field of Psychiatry and Mental Health since its inception in 1975. With an ISSN of 0035-6484 and an E-ISSN of 2038-2502, this esteemed journal offers a platform for rigorous academic discourse and cutting-edge research, helping to shape contemporary psychiatric practices and theories. Currently holding a Q2 designation in Psychiatry and Mental Health based on the 2023 category quartiles, and ranking #197 out of 567 in Scopus, it reflects a commendable 65th percentile among its peers. The journal welcomes contributions that encompass a broad range of topics related to mental health, encouraging contributions from a multidisciplinary approach, which aids in its goal of advancing the understanding and application of psychiatric science. While it is a traditional journal without Open Access options, access to its valuable content can support researchers, clinicians, and students in their pursuit of knowledge and innovation within the field. Situated in Rome, Italy, at VIA SAN GIOVANNI VALDARNO 8, ROME 00138, the journal continues to enhance its rich legacy, promoting the exchange of ideas and fostering collaboration amongst practitioners and scholars alike.

SCHIZOPHRENIA BULLETIN, published by Oxford University Press, stands as a leading journal in the field of psychiatry and mental health, particularly focusing on the complexities of schizophrenia. Established in 1973, this esteemed journal covers a wide spectrum of research areas, including clinical findings, neurobiology, epidemiology, and treatment approaches, making it indispensable for researchers and practitioners alike. With its current status in the Q1 category of the psychiatry and mental health disciplines, and a remarkable Scopus rank of #34 out of 567, the journal enjoys a strong impact factor, emphasizing its contribution to advancing knowledge in mental health. Although it operates on a subscription model, the significance of the journal in disseminating groundbreaking research makes it a vital resource for those committed to improving outcomes in schizophrenia. Through its rigorous peer-review process and commitment to high-quality scientific communication, SCHIZOPHRENIA BULLETIN continues to be at the forefront of psychiatric research and discourse.

The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

Annals of General Psychiatry is a leading open-access journal published by BMC, dedicated to advancing the field of psychiatry and mental health. Since its inception in 2005, the journal has provided a robust platform for researchers to disseminate peer-reviewed clinical and experimental studies, case reports, and reviews that address the broad spectrum of psychiatric disorders. With an impressive Q1 ranking in Psychiatry and Mental Health for 2023, and a notable Scopus rank of #128 out of 567 in its category, the journal plays a pivotal role in disseminating high-quality, impactful research within the global scientific community. The open access model guarantees wide visibility and accessibility of research findings, ensuring that professionals, students, and policymakers can utilize the latest advancements in the psychiatric field. The journal's presence from 2002 to 2024 further demonstrates its commitment to contributing valuable insights that are relevant to contemporary challenges in mental health.

ACTA PSYCHIATRICA SCANDINAVICA is a leading journal in the field of Psychiatry and Mental Health, published by Wiley since its inception in 1926. With a strong commitment to advancing psychiatric research, this esteemed journal boasts an impressive impact factor and ranks within the top 7% of its category, reflecting its influence and relevance in the field. Operating without an Open Access model, the journal serves as a vital resource for professionals, researchers, and students keen on accessing high-quality, peer-reviewed studies focused on mental health issues. The scope of ACTA PSYCHIATRICA SCANDINAVICA spans a broad spectrum of psychiatric topics, providing a platform for groundbreaking research and clinical practice insights. Based in the United Kingdom and featuring contributions from experts worldwide, the journal continues to shape the future of psychiatric research through its rigorous publication standards and commitment to scholarly excellence.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Annals of Clinical Psychiatry, published by QUADRANT HEALTHCOM INC, is a leading journal in the fields of Medicine and Psychiatry & Mental Health. With its longstanding commitment to advancing clinical knowledge since 1989, this esteemed journal contributes invaluable insights into current psychiatric practices and mental health research. The journal is recognized in the Scopus ranking with a position in the 34th percentile, reflective of its focused scope and substantial academic contributions. While access to the journal is tailored for professionals and researchers, the absence of Open Access highlights the journal's dedication to maintaining quality and rigorous peer-reviewed standards. As part of the Q3 quartile for both Medicine and Psychiatry categories in 2023, Annals of Clinical Psychiatry serves as an essential resource for those dedicated to improving mental health outcomes, making it a vital platform for practitioners, researchers, and students alike. Situated in Parsippany, New Jersey, the journal remains a pivotal entity that fosters scholarly dialogue and exploration in clinical psychiatry.

European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.